Partners Multiple Sclerosis Center  
 

NAVIGATION

 

MS Natural History Study

 

HEADLINES

Home Blog Post

 
Comprehensive Longitudinal Investigation of Multiple Sclerosis
at Brigham and Women’s Hospital 

 

 

 
CLIMB Study Group, Summer 2015

 

 

The CLIMB study is a large-scale, long-term study of patients with MS.  It is designed to investigate the course of the disease in the current era of treatment.   The main goals of the study are to:

1. Identify predictors of future disease course when patients are at the beginning of their illness.
2. Determine the effects of treatment on disease progression and accumulation of disability.

Subjects will have neurological exams and MRI yearly.  Subjects will also donate blood samples and complete quality of life and mood questionnaires yearly.

Eligible subjects are those with:
1. Diagnosis of MS or monosymptomatic disease
2. 18 years of age or older
3. Willing to have MRI yearly
4. Willing to donate blood samples and complete questionnaires yearly

                                                                         

 

Howard Weiner, M.D.

 Principal Investigator

 

Tanuja Chitnis, M.D.

Medical Director

 

 

LEAD STUDY STAFF

Bonnie Glanz, Ph.D., Director of Clinical Research Operations

Sandra Cook, R.N., Research Nurse

Mira Weiner, Project Manager

 

 

RESEACH FELLOWS

  Camilo Diaz-Cruz, M.D.

  Neda Sattarnezhad, M.D.

 

 

STUDY COORDINATORS

 Kaitlynne Leclaire, B.A.
   Emily Chan, B.A.
  Tessa Eagle, B.Sc.
  Adrianna Ratajska, B.Sc.
 

 

  BIOSTATISTICS & BIOINFORMATICS

Brian Healy, Ph.D.

Cindy Gonzalez, B.Sc.
  Hrishikesh Lokhande, M.S.
 

 

  INFORMATION SYSTEMS

Marianne Polgar-Turcsanyi, M.S.

 Mark Anderson

Adam Polgar

 

 

NEUROIMAGING RESEARCH

Charles Guttman, M.D.

Rohit Bakshi, M.D.

Svetlana Egorova, M.D., Ph.D.

 

 

 

  PUBLICATIONS:

 

  1. Alterations of the human gut microbiome in multiple sclerosis. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL. Nat Commun. 2016 Jun 28;7:12015. PMID: 27352007;  PMCID: PMC4931233.
  2. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Regev K, Paul A, Healy B, von Glenn F, Diaz-Cruz C, Gholipour T, Mazzola MA, Raheja R, Nejad P, Glanz BI, Kivisakk P, Chitnis T, Weiner HL, Gandhi R. Neurol Neuroimmunol Neuroinflamm. 2016 Aug 23;3(5):e267. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2016 Oct 07;3(6):e296. PMID: 27606352; PMCID: PMC4996540.
  3. Risk attitudes and risk perceptions in individuals with multiple sclerosis. Glanz BI, Greeke E, LaRussa A, Stuart F, Rintell DJ, Chitnis T, Healy BC. Mult Scler-Experimental, Translational and Clinical. 2016;21-11.
  4. Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset. Bove R, Chua AS, Xia Z, Chibnik L, De Jager PL, Chitnis T.  Neurol Genet. 2016 Jul 26;2(4):e88. eCollection 2016 Aug. PMID: 27504495.
  5. Longitudinal BMI trajectories in multiple sclerosis: Sex differences in association with disease severity. Bove R, Musallam A, Xia Z, Baruch N, Messina S, Healy BC, Chitnis T.  Mult Scler Relat Disord. 2016 Jul;8:136-40. PMID: 27456889.
  6. The Contribution of Cortical Lesions to a Composite MRI Scale of Disease Severity in Multiple Sclerosis. Yousuf F, Kim G, Tauhid S, Glanz BI, Chu R, Tummala S, Healy BC, Bakshi R.  Front Neurol. 2016 Jun 29;7:99. eCollection 2016. PMID: 27445966; PMCID: PMC4925661.
  7. Alterations of the human gut microbiome in multiple sclerosis. Jangi S, Gandhi R, Cox LM, Li N, von Glehn F, Yan R, Patel B, Mazzola MA, Liu S, Glanz BL, Cook S, Tankou S, Stuart F, Melo K, Nejad P, Smith K, Topçuolu BD, Holden J, Kivisäkk P, Chitnis T, De Jager PL, Quintana FJ, Gerber GK, Bry L, Weiner HL.  Nat Commun. 2016 Jun 28;7:12015. PMID: 27352007;  PMCID: PMC4931233.
  8. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Mult Scler. 2016 June;22(7):935-43. [Epub ahead of print]. PMID: 26447063.
  9. A longitudinal uncontrolled study of cerebral gray matter volume in patients receiving natalizumab for multiple sclerosis. Int J Neurosci. Khalid F, Tauhid S, Chua AS, Healy BC, Stankiewicz JM, Weiner HL, Bakshi R. 2016 May 27. PMID: 27143245.
  10. The Effect of Fingolimod on Conversion of Acute Gadolinium-Enhancing Lesions to Chronic T1 Hypointensities in Multiple Sclerosis. Oommen VV, Tauhid S, Healy BC, Chua AS, Malik MT, Diaz-Cruz C, Dupuy SL, Weiner HL, Chitnis T, Bakshi R. J Neuroimaging. 2016 Mar;26(2):184-7. PMID: 26445919.
  11. Cognitive and patient-reported outcomes in adults with pediatric multiple sclerosis. Baruch NF, O'Donnell EH, Glanz BI, Benedict RH, Musallam AJ, Healy BC, Rintell D, Chitnis T. Mult Scler. 2016 Mar;22(3):354-61. PMID: 26041802.
  12. An MRI-defined measure of cerebral lesion severity to assess therapeutic effects in  multiple sclerosis. Kim G, Tauhid S, Dupuy SL, Tummala S, Khalid F, Healy BC, Bakshi R.  J Neurol. 2016 Mar;263(3):531-8. PMID: 26754005; PMCID: PMC4785194.
  13. Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Cavallari M, Palotai M, Glanz BI, Egorova S, Prieto JC, Healy BC, Chitnis T, Guttmann CR. Mult Scler. 2016 Feb 26. [Epub ahead of print]. PMID: 26920374.
  14. Genes and Environment in Multiple Sclerosis project: A platform to investigate multiple sclerosis risk. Xia Z, White CC, Owen EK, Von Korff A, Clarkson SR, McCabe CA, Cimpean M, Winn PA, Hoesing A, Steele SU, Cortese IC, Chitnis T, Weiner HL, Reich DS, Chibnik LB, De Jager PL. Ann Neurol. 2016 Feb;79(2):178-89. PMID: 26583565; PMCID: PMC4778957.
  15. Identification of a novel mechanism of action of fingolimod (FTY720) on human effector T cell function through TCF-1 upregulation. Mazzola MA, Raheja R, Murugaiyan G, Rajabi H, Kumar D, Pertel T, Regev K, Griffin R, Aly L, Kivisakk P, Nejad P, Patel B, Gwanyalla N, Hei H, Glanz B, Chitnis T, Weiner HL, Gandhi R. J Neuroinflammation. 2015 Dec 30;12:245. PMID: 26714756; PMCID: PMC4696082.
  16. Patient-reported outcomes in multiple sclerosis: Relationships among existing scales and the development of a brief measure. Chua AS, Glanz BI, Guarino AJ, Cook SL, Greeke EE, Little GE, Chitnis T, Healy BC.  Mult Scler Relat Disord. 2015 Nov;4(6):598-606. PMID: 26590669.
  17. Brain MRI leasions and atrophy are associated with employment status in patient multiple sclerosis. Tauhid S, Chu R, Sasane R, Glanz BI, Neema M, Miller JR, Kim G, Signorovitch JE, Healy BC, Chitnis T, Weiner HL, Bakshi R. J Neurol. 2015 Nov;262(11):2425-32. PMID: 26205635.
  18. Effect of vitamin D on MS activity by disease-modifying therapy class. Rotstein DL, Healy BC, Malik MT, Carruthers RL, Musallam AJ, Kivisakk P, Weiner HL, Glanz BI, Chitnis T.  Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e167. PMID: 26568968, PMCID: PMC4630683.
  19. The 2D:4D ratio, a proxy for prenatal androgen levels, differs in men with and without MS. Bove R, Malik MT, Diaz-Cruz C, Chua A, Saraceno TJ, Bargiela D, Greeke E, Glanz BI, Chitnis T. Neurology. 2015 Oct 6;85(14):1209-13. PMID: 26341868.
  20. Removing confounding factors via constraint-based clustering: An application to finding homogenous groups of multiple sclerosis patients. Liu J, Brodley CE, Healy BC, Chitnis T. Artif Intell Med. 2015 Oct;65(2):79-88. PMID: 26253753.
  21. Using multiple imputation to efficiently correct cerebral MRI whole brain lesion and atrophy data in patients with multiple sclerosis. Chua AS, Egorova S, Anderson MC, Polgar-Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Neuroimage. 2015 Oct1;119:81-8. PMID: 26093330.
  22. T1- vs. T2-based MRI measures of spinal cord volume in healthy subjects and patients with multiple sclerosis. Kim G, Khalid F, Oommen VV, Tauhid S, Chu R, Horsfield MA, Healy BC, Bakshi R. BMC Neurol. 2015 Jul 31;15:124. PMID: 26227960; PMCID:PMC4521382.
  23. Handling changes in MRI acquisition parameters in modeling whole brain lesion volume and atrophy data in multiple sclerosis subjects: Comparison of linear mixed-effect models. Chua AS, Egorova S, Anderson MC, Polgar-Turcsanyi M, Chitnis T, Weiner HL, Guttmann CR, Bakshi R, Healy BC. Neuroimage Clin. 2015 Jul 2;8:606-10. eCollection 2015. PMID: 26199872; PMCID: PMC4506959.
  24. A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Esposito F, Sorosina M, Ottoboni L, Lim ET, Replogle JM, Raj T, Brambilla P, Liberatore G, Guaschino C, Romeo M, Pertel T, Stankiewicz JM, Martinelli V, Rodegher M, Weiner HL, Brassat D, Benoist C, Patsopoulos NA, Comi G, Elyaman W, Martinelli Boneschi F, De Jager PL.  Ann Neurol. 2015 Jul;78(1):115-27. PMID: 25914168.
  25. Progression rates and sample size estimates for PPMS based on the CLIMB study population. Raghavan K, Healy BC,Carruthers RL, Chitnis T. Mult Slero. 2015 Feb;21(2):180-8. PMID: 25070676.
  26. Joint assessment of dependent discrete disease state processes. Engler D, Chitnis T, Healy BC. Stat Methods Med Res. 2015 Feb 19 [Epub ahead of print]. PMID: 25698716.
  27. Evaluation of no evidence disease activity in a 7-year old longitudinal multiple sclerosis cohort. Rotstein DL, Healy BC, Malik MT, Chitnis T, Weiner HL. JAMA Neurol. 2015 Feb;72(2):152-8. PMID: 25531931.
  28. Patients report worse MS symptoms after menopause: findings from an online cohort. Bove R, Healy BC, Secor E, Vaughan T, Katic B, Chitnis T, Wicks P, De Jager PL. Mult Scler Relat Disord. 2015 Jan;4(1):18-24. PMID: 25787049.
  29. Addressing Human Subjectivity via Transfer Learning: An Application to Predicting Disease Outcome in Multiple Sclerosis Patients. Zhao Y, Brodley CE, Chitnis T, Healy BC. Proceedings of the 2014 SIAM International Conference on Data Mining. p965-73, 2014.
  30. MRI phenotypes based on cerebral lesions and atrophy in patients with multiple sclerosis. Tauhid S, Neema M, Healy BC, Weiner HL, Bakshi R. Journal of the Neurological Sciences. 2014;346:250-54. PMID: 25220114.
  31. An expanded composite scale of MRI-defined disease severity in multiple sclerosis: MRDSS2. Bakshi R, Neema M, Tauhid S, Healy BC, Glanz BI, Kim G, Miller J, Berkowitz JL, Bove R, Houtchens MK, Severson C, Stankiewicz JM, Stazzone L, Chitnis T, Guttmann CR, Weiner HL, Ceccarelli A. Neuroreport. 2014 Oct 1;25(14):1156-61. PMID: 25100554.
  32. Low testosterone is associated with disability in men with multiple sclerosis. Bove R, Musallam A, Healy B Raghavan K, Glanz B, Bakshi R, Weiner H, De Jager P, Miller K, Chitnis T. Mult Scler. 2014 Oct;20(12):1584-92. PMID: 24710799; PMCID: PMC4188801.
  33. An observational comparison of natalizumab vs. fingolimod using JCV serology to determine therapy. Carruthers RL, Rotstein DL, Healy BC, Chitnis T, Weiner HL, Buckle GJ. Mult Scler. 2014 Sep;20(10):1381-90. PMID: 24852928.
  34. Factors associated with recovery from acute optic neurtis in patiens with multiple sclerosis. Malik MT, Healy BC, Benson LA, Kivisäkk P, Musallam A, Weiner HL, Chitnis T. Neurology. 2014 Jun 17;82(24):2173-9. PMID: 24850491;PMCID: PMC:4113460.
  35. Treatment satisfaction in multple sclerosis. Glanz BI, Musallam A, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Int Journal MS Care. 2014 Summer;16(2):68-75. PMID: 25061430; PMCID: PMC4106393.
  36. Menopause in multiple sclerosis: therapeutic considerations. Bove R, Chitnis T, Houtchens M. J Neurol. 2014 Jul;261(7):1257-68. Review. PMID: 24101131.
  37. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy. Carruthers RL, Chitnis T, Healy BC. Mult Scler. 2014 May;20(6):757-60. PMID: 24189572.
  38. Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ. Mult Scler. 2014 Apr;20(4):438-44. PMID: 24005026.
  39. Elevated relapse rate in pediatric compared to adult MS persis for at least 6 years. Benson LA, Healy BC, Gorman MP, Baruch NF, Gholipour T, Musallam A, Chitnis T. Mult Sler  Relat Disord. 2014 Mar3(2):186-93. PMID: 25878006.
  40. Clinical relevance and functional  consequences of the TNFRSF1A multiple sclerosis locus. Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL, Hafler DA, De Jager PL. Neurology. 2013 Nov 26;81(22):1891-9. PMID: 24174586; PMCID: PMC3843384.
  41. Quantitative MRI analysis in children with multiple sclerosis: a multicenter feasibility pilot study. Chitnis T, Guttmann CR, Zaitsev A, Musallam A, Weinstock-Guttman B, Yeh A, Rodriguez M, Ness J, Gorman MP, Healy BC, Kuntz N, Chabas D, Strober JB, Waubant E, Krupp L, Pelletier D, Erickson B, Bergsland N, Zivadinov R; U.S. Network of Pediatric MS Centers of Excellence. BMC Neurol. 2013 Nov 13;13:173. PMID: 24225378; PMCID: PMC3832402.
  42. Modeling disease severity in multiple sclerosis using electronic health records. Xia Z, Secor E, Chibnik LB, Bove RM, Cheng S, Chitnis T, Cagan A, Gainer VS, Chen PJ, Liao KP, Shaw SY, Ananthakrishnan AN, Szolovits P, Weiner HL, Karlson EW, Murphy SN, Savova GK, Cai T, Churchill SE, Plenge RM, Kohane IS, De Jager PL. PLoS One. 2013 Nov 11;8(11):e78927. eCollection 2013. PMID: 24244385; PMCID: PMC3823928.
  43. Removing Confounding Factors via Constraint-Based Clustering: An Application to Finding Homogeneous Groups of MS Patients. Liu J, Brodley CE, Healy BC, Chitnis T. Data Mining for Healthcare Workshop at ICHI, 2013. 
  44. Increased leptin and A-FABP levels in relapsing and progressive forms of MS. Messina S,Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, Bove, R, Gholipou T, Khoury SJ, Weiner HL, Chitnis T. BMC Neurol. 2013 Nov 11;13:172. PMID: 2421502; PMCID: PMC3829106.
  45. Sexual disparities in the incidence and course of MS. Bove R, Chitnis T. Clin Immunol. 2013 Nov;149(2):201-10. Epub 2013 Mar 22. Review. PubMed PMID: 23608496.
  46. Sex influences in autoimmune disease. Chitnis T, Khoury SJ. Clin Immunol. 2013 Nov;149(2):169. PMID: 24012474.
  47. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. International Multiple Sclerosis Genetics Consortium (IMSGC), Beecham AH, atsopoulos NA, Xifara DK, Davis MF, Kemppinen A, Cotsapas C, Shah TS, Spencer C, Booth D, Goris A, Oturai A, Saarela J, Fontaine B, Hemmer B, Martin C, Zipp F, D'Alfonso S, Martinelli-Boneschi F, Taylor B, Harbo HF, Kockum I, Hillert J, Olsson T, Ban M, Oksenberg JR, Hintzen R, Barcellos LF; Wellcome Trust Case Control Consortium 2 (WTCCC2); International IBD Genetics Consortium (IIBDGC), Agliardi C, Alfredsson L, Alizadeh M, Anderson C, Andrews R, Søndergaard HB, Baker A, Band G, Baranzini SE, Barizzone N, Barrett J, Bellenguez C, Bergamaschi  L, Bernardinelli L, Berthele A, Biberacher V, Binder TM, Blackburn H, Bomfim IL,  Brambilla P, Broadley S, Brochet B, Brundin L, Buck D, Butzkueven H, Caillier SJ, Camu W, Carpentier W, Cavalla P, Celius EG, Coman I, Comi G, Corrado L, Cosemans  L, Cournu-Rebeix I, Cree BA, Cusi D, Damotte V, Defer G, Delgado SR, Deloukas P,  di Sapio A, Dilthey AT, Donnelly P, Dubois B, Duddy M, Edkins S, Elovaara I, Esposito F, Evangelou N, Fiddes B, Field J, Franke A, Freeman C, Frohlich IY, Galimberti D, Gieger C, Gourraud PA, Graetz C, Graham A, Grummel V, Guaschino C, Hadjixenofontos A, Hakonarson H, Halfpenny C, Hall G, Hall P, Hamsten A, Harley J, Harrower T, Hawkins C, Hellenthal G, Hillier C, Hobart J, Hoshi M, Hunt SE, Jagodic M, Jelčić I, Jochim A, Kendall B, Kermode A, Kilpatrick T, Koivisto K, Konidari I, Korn T, Kronsbein H, Langford C, Larsson M, Lathrop M, Lebrun-Frenay  C, Lechner-Scott J, Lee MH, Leone MA, Leppä V, Liberatore G, Lie BA, Lill CM, Lindén M, Link J, Luessi F, Lycke J, Macciardi F, Männistö S, Manrique CP, Martin R, Martinelli V, Mason D, Mazibrada G, McCabe C, Mero IL, Mescheriakova J, Moutsianas L, Myhr KM, Nagels G, Nicholas R, Nilsson P, Piehl F, Pirinen M, Price SE, Quach H, Reunanen M, Robberecht W, Robertson NP, Rodegher M, Rog D, Salvetti  M, Schnetz-Boutaud NC, Sellebjerg F, Selter RC, Schaefer C, Shaunak S, Shen L, Shields S, Siffrin V, Slee M, Sorensen PS, Sorosina M, Sospedra M, Spurkland A, Strange A, Sundqvist E, Thijs V, Thorpe J, Ticca A, Tienari P, van Duijn C, Visser EM, Vucic S, Westerlind H, Wiley JS, Wilkins A, Wilson JF, Winkelmann J, Zajicek J, Zindler E, Haines JL, Pericak-Vance MA, Ivinson AJ, Stewart G, Hafler  D, Hauser SL, Compston A, McVean G, De Jager P, Sawcer SJ, McCauley JL. Nat Genet. 2013 Nov;45(11):1353-60. PMID: 24076602, PMCID: PMC3832895.
  48. No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. Bove R, Musallam A, Healy BC, Houtchens M, Glanz BI, Khoury S, Guttmann CR, De Jager PL, Chitnis T. BMC Neurol. 2013 Jul 3;13:73. PMID: 23822612.
  49. Assessment of definitions of sustained disease progression in relapsing-remitting multiple sclerosis. Healy BC, Engler D, Glanz B, Musallam A, Chitnis T. Mult Scler Int. 2013;2013:189624. PMID: 23555057.
  50. Evaluation of an online platform for multiple sclerosis research: patient description, validation of severity scale, and exploration of BMI effects on disease course. Bove R, Secor E, Healy BC, Musallam A, Vaughn T, Glanz BI, Greeke E, Weiner HL, Chitnis T, Wicks P, De Jager PL. PLoS One. 2013;8(3):e59707. PMID: 23527256.
  51. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Gandhi R, HealyB, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL. Ann Neurol. 2013 Jun;73(6):729-40. PMID: 23494648.
  52. Increased Th17 response to myelin peptides in pediatric MS. Vargas-Lowy D, Kivisakk P, Gandhi R, Raddassi K, Soltany P, Gorman MP, Khoury SJ, Chitnis T. Clin Immunol. 2012 Dec 28;146(3):176-84. PMID: 23352968.
  53. The impact of a recent relapse on patient-reported outcomes in subjects with multiple sclerosis. Healy BC, Degano IR, Schreck A, Rintell D, Weiner H, Chitnis T, Glanz BI. Qual Life Res. 2012 Dec;21(10):1677-84. PMID: 22237991.
  54. Work productivity in relapsing multiple sclerosis: associations with disability, depression, fatigue, anxiety, cognition, and health-related quality of life. Glanz, BI, Degano IR, Rintell DJ, Chitnis T, Weiner HL, Healy BC. Value Health. 2012 Dec;15(8):1029-35. PMID: 23244804.
  55. Effect of gender on late-onset multiple sclerosis. Bove RM, Healy B, Augustine A, Musallam A, Gholipour T, Chitnis T. Mult Scler. 2012 Oct;18(10):1472-9. PMID 22383227.
  56. The impact of lesion in-painting and registration methods on voxel-based morphometry in detecing regional cerebral gray matter atrophy in multiple sclerosis. Cecciarelli A, Jackson JS, Tauhid S, Arora A, Gorky J, Dell'Oglio E, Bakshi A, Chitnis T, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R, Neema M. AJNR Am J Neuroradiol. 2012 Sep;33(8):1579-85. PMID: 22460341.
  57. An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity . Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL. Sci Transl Med. 2012 Sep 26;4(153):153ra131. PMID: 23019656; PMCID: PMC3753678.
  58. Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: A longitudinal study.  Moodie J, Healy BC, Buckle GJ, Gauthier SA, Glanz BI, Arora A, Ceccarelli A, Tauhid S, Han XM, Venkataraman A, Chitnis T, Khoury SJ, Guttmann CR, Weiner HL, Neema M, Bakshi R. J Neurol Sci. 2012 Apr 15;315(1-2):49-54. PMID: 22209496; PMCID: PMC22209496
  59. CADASIL mutation and Balo concentric sclerosis: a link between demyelination and ischemia? Chitnis T, Hollmann TJ. Neurology. 2012 Jan 17;78(3):221-3. PMID: 22218279; PMCID: PMC3466606.
  60. Cognitive deterioration in patients with early multiple sclerosis: a 5-year study. Glanz BI, Healy BC, Hviid LE, Chitnis T, Weiner HL. J Neurol Neurosurg Psychiatry. 2012 Jan;83(1):38-43. PMID: 21746743.
  61. Improving power to detect disease progression in multiple sclerosis through alternative analysis strategies. Healy B, Chitnis T, Engler D. J Neurol. 2011 Oct; 258(10):1812-9. PMID: 21472497.
  62. Patient reported outcomes in benign multiple sclerosis. Hviid L, Healy B, Rintell D, Chitnis T, Weiner H, Glanz B. J Mult Scler. 2011 Jul;17(7):876-84. PMID: 21372114.
  63. Brain MRI Lesion Load at 1.5T and 3T versus Clinical Status in Multiple Sclerosis. Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, Guss ZD, Tauhid S, Buckle GJ, Houtchens MK, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. J Neuroimaging. 2011 Apr;21(2):e50-6. PMID: 19888926; PMCID: PMC3043123.
  64. Demographic and clinical characteristics of malignant multiple sclerosis. Gholipour T, Healy B, Baruch NF, Weiner HL, Chitnis T. Neurology. 2011 Jun 7;76(23):1996-2001. PMID: 21646626.
  65. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis. Healy BC, Engler D, Gholipour T, Weiner H, Bakshi R, Chitnis T. J Neurol Sci. 2011 Apr 15;303(1-2):109-13. PMID: 21251671
  66. Population structure and HLA DRB1*1501 in the response of subjects with multiple sclerosis to first-line treatments.Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL. J Neuroimmunol. 2011 Apr;233(1-2):168-74. PMID: 21115201.
  67. A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis . Xia Z, Chibnik LB, Glanz BI, Liguori M, Shulman JM, Tran D, Khoury SJ, Chitnis T, Holyoak T, Weiner HL, Guttmann CR, De Jager PL. PLoS One. 2010 Nov 30;5(11):e14169. PMID: 21152065
  68. A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S. Arch Neurol. 2010 Sep;67(9):1055-6. PMID: 20837847; PMCID: PMC2954052. 
  69. Seasonal prevalence of MS disease activity. Meier DS, Balashov KE, Healy B, Weiner HL, Guttmann CR. Neurology. 2010 Aug 31;75(9):799-806. PMID: 20805526; PMCID: PMC2938966.
  70. A method for evaluating treatment switching criteria in multiple sclerosis. Healy BC, Glanz BI, Stankiewicz J, Buckle G, Weiner H, Chitnis T. Mult Scler. 2010  Dec;16(12):1483-9. PMID: 20736245.
  71. HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL. Neurology. 2010 Aug 17;75(7):634-40. PMID: 20713950; PMCID: PMC2931768.
  72. The association between cognitive impairment and quality of life in patients with early multiple sclerosis. Glanz BI, Healy BC, Rintell DJ, Jaffin SK, Bakshi R, Weiner HL. J Neurol Sci. 2010 Mar 15;290(1-2):75-9. PMID: 19944429.
  73. Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL. J Neurol Sci. 2009 Sep 15;284(1-2):116-9. PMID: 19428028.  
  74. Regional white matter atrophy--based classification of multiple sclerosis in cross-sectional and longitudinal data. Sampat MP, Berger AM, Healy BC, Hildenbrand P, Vass J, Meier DS, Chitnis T, Weiner HL, Bakshi R, Guttmann CR. AJNR Am J Neuroradiol. 2009 Oct;30(9):1731-9. PMID: 19696139; PMCID: PMC2821733.
  75. Smoking and disease progression in multiple sclerosis. Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A. Arch Neurol. 2009 Jul;66(7):858-64. PMID: 19597087; PMCID: PMC2754172.
  76. Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ. Neurology. 2009 Jun 2;72(22):1922-30. PMID: 19487650; PMCID: PMC2690969.
  77. Demographics of pediatric-onset multiple sclerosis in an MS center population from the Northeastern United States. Chitnis T, Glanz B, Jaffin S, Healy B. Mult Scler. 2009 May;15(5):627-31. Epub 2009 Mar 19. PMID: 19299440. 
  78. Spinal cord lesions and clinical status in multiple sclerosis: A 1.5 T and 3 T MRI study. Stankiewicz JM, Neema M, Alsop DC, Healy BC, Arora A, Buckle GJ, Chitnis T, Guttmann CR, Hackney D, Bakshi R. J Neurol Sci. 2009 Apr 15;279(1-2):99-105. PMID: 19178916.
  79. Rate of brain atrophy in benign vs early multiple sclerosis.  Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR.  Arch Neurol. 2009 Feb;66(2):234-7.  PMID: 19204160. 
  80. Daclizumab in treatment of multiple sclerosis patients. Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ. Mult Scler. 2009 Feb;15(2):272-4. PMID: 19136546.
  81. Increased relapse rate in pediatric-onset compared with adult-onset multiple sclerosis.  Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Arch Neurol. 2009 Jan;66(1):54-9. PMID: 19139299 
  82. Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R. J Neuroimaging. 2009 Jan;19(1):3-8. PMID: 19192042; PMCID: PMC2762230. 
  83. Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL.  Arch Neurol. 2008 Nov;65(11):1449-53. PMID: 19001162; PMCID: PMC2762216.
  84. CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.  Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ. Neurology. 2008 Sep 16;71(12):917-24. PMID: 18794494.
  85. Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis.  Liptak Z, Berger AM, Sampat MP, Charil A, Felsovalyi O, Healy BC, Hildenbrand P, Khoury SJ, Weiner HL, Bakshi R, Guttmann CR.AJNR Am J Neuroradiol. 2008 Sep;29(8):1465-70. PMID: 18556361.
  86. Estimating Time to Event From Longitudinal Categorical Data: An Analysis of Multiple Sclerosis Progression. Mandel M, Gauthier SA, Guttmann CR, Weiner HL, Betensky RA. J Am Stat Assoc. 2007 Dec;102(480):1254-1266. PMID: 19081806
  87. Predicting short-term disability in multiple sclerosis. Gauthier SA, Mandel M, Guttmann CR, Glanz BI, Khoury SJ, Betensky RA, Weiner HL.  Autoimmun Rev. 2006 Oct;5(8):532-6. Review. PMID: 17027888
  88. A model for the comprehensive investigation of a chronic autoimmune disease: the mulitple sclerosis CLIMB study. Gauthier SA, Glanz BI, Mandel M, Weiner HL. Autoimmun Rev. 2006 Oct;5(8):532-6. Review.


 

 

© Copyright ® Partners MS Center, 2007, E-Mail Webmaster